Show simple item record

dc.contributor.authorMurphy, R A
dc.contributor.authorMarconi, V C
dc.contributor.authorGandhi, R T
dc.contributor.authorKuritzkes, D R
dc.contributor.authorSunpath, H
dc.date.accessioned2013-07-04T20:47:22Z
dc.date.available2013-07-04T20:47:22Z
dc.date.issued2012-09-28
dc.date.submitted2013-06-20
dc.identifier.citationCoadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. 2012, 7 (9):e44793 PLoS ONEen_GB
dc.identifier.issn1932-6203
dc.identifier.pmid23028623
dc.identifier.doi10.1371/journal.pone.0044793
dc.identifier.urihttp://hdl.handle.net/10144/295261
dc.description.abstractIn HIV-infected patients receiving rifampicin-based treatment for tuberculosis (TB), the dosage of lopinavir/ritonavir (LPV/r) is adjusted to prevent sub-therapeutic lopinavir concentrations. In this setting, South African clinicians were advised to administer super-boosted LPV/r (400 mg/400 mg) twice daily, instead of standard dosed LPV/r (400 mg/100 mg) twice daily. We sought to determine--in routine practice--the tolerability and HIV treatment outcomes associated with super-boosted LPV/r compared to unadjusted LPV/r in combination with rifampicin-based TB treatment.
dc.language.isoenen
dc.publisherPublic Library of Scienceen_GB
dc.rightsPublished by Public Library of Science, [url]http://www.plosone.org/[/url] Archived on this site by Open Access permission.en_GB
dc.subjectHIV/AIDSen_GB
dc.subjectTuberculosisen_GB
dc.subject.meshAdolescenten_GB
dc.subject.meshAdulten_GB
dc.subject.meshAnti-HIV Agentsen_GB
dc.subject.meshAntibiotics, Antitubercularen_GB
dc.subject.meshChilden_GB
dc.subject.meshCoinfectionen_GB
dc.subject.meshDrug Therapy, Combinationen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHIV-1en_GB
dc.subject.meshHumansen_GB
dc.subject.meshKaplan-Meier Estimateen_GB
dc.subject.meshLopinaviren_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshRifampinen_GB
dc.subject.meshRitonaviren_GB
dc.subject.meshSouth Africaen_GB
dc.subject.meshTime Factorsen_GB
dc.subject.meshTuberculosisen_GB
dc.subject.meshYoung Adulten_GB
dc.titleCoadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africaen
dc.contributor.departmentMedical Unit, Médecins Sans Frontières/Doctors Without Borders, New York, New York, United States of Americaen_GB
dc.identifier.journalPloS Oneen_GB
refterms.dateFOA2019-03-04T10:39:25Z
html.description.abstractIn HIV-infected patients receiving rifampicin-based treatment for tuberculosis (TB), the dosage of lopinavir/ritonavir (LPV/r) is adjusted to prevent sub-therapeutic lopinavir concentrations. In this setting, South African clinicians were advised to administer super-boosted LPV/r (400 mg/400 mg) twice daily, instead of standard dosed LPV/r (400 mg/100 mg) twice daily. We sought to determine--in routine practice--the tolerability and HIV treatment outcomes associated with super-boosted LPV/r compared to unadjusted LPV/r in combination with rifampicin-based TB treatment.


Files in this item

Thumbnail
Name:
Murphy et al- 2012 - Coadminis ...
Size:
234.4Kb
Format:
PDF
Description:
Main article

This item appears in the following Collection(s)

Show simple item record